Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. FUJIFILM Holdings Corporation
  6. News
  7. Summary
    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FUJIFILM : Japan's Fujifilm says it can make new coronavirus variant detection kits in weeks

05/18/2021 | 02:29am EDT

TOKYO, May 18 (Reuters) - A unit of Japan's Fujifilm Holdings Corp said on Tuesday it can develop detection kits for new variants of the coronavirus in about a month, responding to concerns over the spread of more infectious strains of the virus.

Fujifilm Wako Pure Chemical Corp developed a kit that can identify the L452R variant, first identified in India and California and recently discovered in Tokyo. That adds to kits that can detect two other strains of the virus used by public health authorities as early warning systems for infection trends.

"It's very important to control the mutant strains in the early stages of their spread," Kuniaki Okamoto, general manager of the company's life sciences operations, told Reuters in an interview.

Much of Japan is under a state of emergency as a fourth wave of COVID-19 assails the country with about two months to go until the planned opening of the Tokyo Olympics.

Western Japan has been particularly hard hit from a more-infectious strain first discovered in Britain, while Tokyo Governor Yuriko Koike sounded alarm last week about the discovery of the Indian variant in the capital.

Fujifilm Wako's kit uses reagent chemicals to detect mutations in the SARS-CoV-2 virus and can deliver results in about 100 minutes. The company is focusing on the Japanese market and will look to export the kits depending on demand and regulatory requirements in other countries, Okamoto said.

Known mainly for its camera and office solutions businesses, Fujifilm's push into healthcare has become all the more apparent amid the pandemic. In addition to developing testing kits, the company is carrying out trials of its antiviral drug Avigan as a COVID-19 treatment.

The company has also invested heavily in Europe and the United States to expand factories involved in making ingredients for vaccines and drugs. (Reporting by Hideto Sakai and Rocky Swift; Editing by Kirsten Donovan)


© Reuters 2021
All news about FUJIFILM HOLDINGS CORPORATION
07/28FUJIFILM : Together for the First Time, FUJIFILM Medical Systems U.S.A., Inc. an..
AQ
07/28FUJIFILM : Business Innovation Launches New Brand for Production Printers (FUJIF..
PU
07/26FUJIFILM : US Radiology Specialists Selects Fujifilm's Synapse Enterprise Inform..
AQ
07/19Charter Hall Long Wale Reit Enters into A Lease for Building C, 56 Edmondston..
CI
07/14FUJIFILM : Launches Virtual Hospital to Showcase that it's Comprehensive Healthc..
AQ
07/12FUJIFILM : finds new niches, record profits amid pandemic
AQ
07/09New Fujifilm CEO focuses on drug ingredients unit after Avigan stumbles
RE
07/01FUJIFILM : closing South Carolina plants; 400 to lose jobs
AQ
06/30FUJIFILM : Business Innovation Announces Management Changes (FUJIFILM Business I..
PU
06/24FUJIFILM : Expands Integrated Inkjet Solutions Business
AQ
More news
Financials
Sales 2022 2 457 B 22 402 M 22 402 M
Net income 2022 148 B 1 352 M 1 352 M
Net Debt 2022 232 B 2 119 M 2 119 M
P/E ratio 2022 21,6x
Yield 2022 1,29%
Capitalization 3 216 B 29 362 M 29 318 M
EV / Sales 2022 1,40x
EV / Sales 2023 1,34x
Nbr of Employees 73 275
Free-Float 73,9%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
FUJIFILM Holdings Corporation Technical Analysis Chart | 4901 | JP3814000000 | MarketScreener
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 8 043,00 JPY
Average target price 8 471,43 JPY
Spread / Average Target 5,33%
EPS Revisions
Managers and Directors
Shigetaka Komori Chairman & Group Chief Executive Officer
Kenji Sukeno President, Group COO & Representative Director
Takashi Iwasaki Director & Chief Technology Officer
Kunitaro Kitamura Independent Outside Director
Tatsuo Kawada Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
FUJIFILM HOLDINGS CORPORATION47.90%29 362
ABBOTT LABORATORIES10.07%215 155
MEDTRONIC PLC11.42%175 621
BECTON, DICKINSON AND COMPANY2.03%74 249
ALIGN TECHNOLOGY, INC.26.69%53 574
HOYA CORPORATION8.86%52 325